The association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Go to Publication You Might Also Like Prevalence of venous thromboembolism in acute exacerbations of chronic obstructive pulmonary disease: an Indian perspective. October 10, 2011 Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease August 30, 2019 Why “covering all” in the DOTS program is not necessarily “all being covered” by the DOTS program. October 29, 2010 Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. February 17, 2015 Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015
Prevalence of venous thromboembolism in acute exacerbations of chronic obstructive pulmonary disease: an Indian perspective. October 10, 2011
Why “covering all” in the DOTS program is not necessarily “all being covered” by the DOTS program. October 29, 2010
Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. February 17, 2015
Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015